Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of Fovista added to Avastin or Eylea for neovascular age-related macular degeneration
2013-003018-42Phase 3Terminated
- Sponsor
- IVERIC bio
- Start
- May 2014
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pegpleranib in exudative macular degeneration, subfoveal choroidal neovascularization (CNV) and age-related macular degeneration (AMD) (4 arms), sponsored by IVERIC bio. Primary endpoint: Mean change in visual acuity from baseline at Month 12. Started May 2014; status: terminated.
02
Drugs
pegpleranib
03
Conditions
exudative macular degenerationsubfoveal choroidal neovascularization (CNV)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2013-003018-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003018-42.